NCT06024239CompletedPhase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
A Multiple Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Subjects With Generalized Anxiety Disorder (GAD) and Subjects With Bipolar Disorder
Source: ClinicalTrials.gov · Last updated 17 Mar 2025
Brief summary (registry, in English)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 30 Aug 2023
- Start date
- Aug 2023
- Primary completion date
- Mar 2025
- Lead sponsor
- AbbVie
- Diseases
- Bipolar disorder
- NCT number
- NCT06024239
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 72
- From Aug 2023 to the primary completion date, Mar 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
Who the study is looking for
- For healthy volunteer cohort:
- \-- Body mass index (BMI) is \>= 18.0 to \<= 32.0 kg/m2 after rounding to the tenths decimal.
- For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD)
- Participants with GAD or BPD (as confirmed by MINI) meet participant psychiatric history criteria described in the protocol.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Acpru /Id# 255945 Coordinator of this site? Confirm its status | Grayslake | United States | Unknown status |
| Collaborative Neuroscience Research CNS /ID# 260270 Coordinator of this site? Confirm its status | Los Alamitos | United States | Unknown status |
| Hassman Research Institute Marlton Site /ID# 260271 Coordinator of this site? Confirm its status | Marlton | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.